444 related articles for article (PubMed ID: 18692325)
1. Effect of family history on outcomes in patients treated with definitive brachytherapy for clinically localized prostate cancer.
Peters CA; Stock RG; Blacksburg SR; Stone NN
Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):24-9. PubMed ID: 18692325
[TBL] [Abstract][Full Text] [Related]
2. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
Ho AY; Burri RJ; Cesaretti JA; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):16-22. PubMed ID: 19289266
[TBL] [Abstract][Full Text] [Related]
3. Young men have equivalent biochemical outcomes compared with older men after treatment with brachytherapy for prostate cancer.
Burri RJ; Ho AY; Forsythe K; Cesaretti JA; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1315-21. PubMed ID: 20044216
[TBL] [Abstract][Full Text] [Related]
4. Predicting biochemical tumor control after brachytherapy for clinically localized prostate cancer: The Memorial Sloan-Kettering Cancer Center experience.
Zelefsky MJ; Chou JF; Pei X; Yamada Y; Kollmeier M; Cox B; Zhang Z; Schechter M; Cohen GN; Zaider M
Brachytherapy; 2012; 11(4):245-9. PubMed ID: 21925957
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcomes in younger men following permanent prostate brachytherapy.
Shapiro EY; Rais-Bahrami S; Morgenstern C; Napolitano B; Richstone L; Potters L
J Urol; 2009 Apr; 181(4):1665-71; discussion 1671. PubMed ID: 19233394
[TBL] [Abstract][Full Text] [Related]
6. Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy.
Eggener SE; Roehl KA; Yossepowitch O; Catalona WJ
J Urol; 2006 Oct; 176(4 Pt 1):1399-403. PubMed ID: 16952643
[TBL] [Abstract][Full Text] [Related]
7. Lack of benefit of pelvic radiation in prostate cancer patients with a high risk of positive pelvic lymph nodes treated with high-dose radiation.
Vargas CE; Galalae R; Demanes J; Harsolia A; Meldolesi E; Nürnberg N; Schour L; Martinez A
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1474-82. PubMed ID: 15964706
[TBL] [Abstract][Full Text] [Related]
8. Patterns of local failure following prostate brachytherapy.
Stone NN; Stock RG; White I; Unger P
J Urol; 2007 May; 177(5):1759-63; duscussion 1763-4. PubMed ID: 17437808
[TBL] [Abstract][Full Text] [Related]
9. Impact of race on biochemical disease recurrence after prostate brachytherapy.
Yamoah K; Stone N; Stock R
Cancer; 2011 Dec; 117(24):5589-600. PubMed ID: 21692058
[TBL] [Abstract][Full Text] [Related]
10. Intermediate-risk localized prostate cancer in the PSA era: radiotherapeutic alternatives.
Gondi V; Deutsch I; Mansukhani M; O'Toole KM; Shah JN; Schiff PB; Katz AE; Benson MC; Goluboff ET; Ennis RD
Urology; 2007 Mar; 69(3):541-6. PubMed ID: 17382161
[TBL] [Abstract][Full Text] [Related]
11. Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy.
Stone NN; Potters L; Davis BJ; Ciezki JP; Zelefsky MJ; Roach M; Shinohara K; Fearn PA; Kattan MW; Stock RG
Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):341-6. PubMed ID: 18597953
[TBL] [Abstract][Full Text] [Related]
12. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
Demanes DJ; Brandt D; Schour L; Hill DR
Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
[TBL] [Abstract][Full Text] [Related]
13. Effect of percentage of positive prostate biopsy cores on biochemical outcome in low-risk PCa treated with brachytherapy or 3D-CRT.
Pe ML; Trabulsi EJ; Kedika R; Pequignot E; Dicker AP; Gomella LG; Valicenti RK
Urology; 2009 Jun; 73(6):1328-34. PubMed ID: 19376564
[TBL] [Abstract][Full Text] [Related]
14. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer.
Potters L; Morgenstern C; Calugaru E; Fearn P; Jassal A; Presser J; Mullen E
J Urol; 2005 May; 173(5):1562-6. PubMed ID: 15821486
[TBL] [Abstract][Full Text] [Related]
15. Prostate brachytherapy: a descriptive analysis from CaPSURE.
Lee WR; Sharkey J; Cowan JE; DuChane J; Carroll PR;
Brachytherapy; 2007; 6(2):123-8. PubMed ID: 17434105
[TBL] [Abstract][Full Text] [Related]
16. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes.
Zelefsky MJ; Yamada Y; Fuks Z; Zhang Z; Hunt M; Cahlon O; Park J; Shippy A
Int J Radiat Oncol Biol Phys; 2008 Jul; 71(4):1028-33. PubMed ID: 18280056
[TBL] [Abstract][Full Text] [Related]
17. Cancer control after low-dose-rate prostate brachytherapy performed by a multidisciplinary team with no previous prostate brachytherapy experience.
McMullen KP; deGuzman AF; McCullough DL; Lee WR
Urology; 2004 Jun; 63(6):1128-31. PubMed ID: 15183965
[TBL] [Abstract][Full Text] [Related]
18. Dose-escalated radiation therapy for intermediate-risk prostate cancer: patient selection for androgen deprivation therapy using percentage of positive cores.
Liauw SL; Fricano J; Correa D; Weichselbaum RR; Jani AB
Cancer; 2009 Apr; 115(8):1784-90. PubMed ID: 19208426
[TBL] [Abstract][Full Text] [Related]
19. Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer.
Morris WJ; Keyes M; Palma D; Spadinger I; McKenzie MR; Agranovich A; Pickles T; Liu M; Kwan W; Wu J; Berthelet E; Pai H
Urology; 2009 Apr; 73(4):860-5; discussion 865-7. PubMed ID: 19168203
[TBL] [Abstract][Full Text] [Related]
20. High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost: results of a phase I to II study.
Vargas CE; Martinez AA; Boike TP; Spencer W; Goldstein N; Gustafson GS; Krauss DJ; Gonzalez J
Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):416-23. PubMed ID: 16879929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
